Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2007 Feb;28(2):75-82. Epub 2007 Jan 10.

Ca2+ channel alpha2delta ligands: novel modulators of neurotransmission.

Author information

1
Department of CNS Pharmacology, Pfizer Global Research and Development, Ann Arbor, MI 48105, USA. david.dooley@pfizer.com

Erratum in

  • Trends Pharmacol Sci. 2007 Apr;28(4):151.

Abstract

The term 'Ca2+ channel alpha2delta ligands' has recently been applied to an evolving drug class that includes gabapentin (Neurontin) and pregabalin (Lyrica), and reflects significant progress over the past decade in elucidating the mechanism of action of these drugs: a novel, specific action at one of the subunits constituting voltage-sensitive Ca2+ channels. Binding of these ligands to the alpha2delta subunit is considered to explain their usefulness in treating several clinical disorders, including epilepsy, pain from diabetic neuropathy, postherpetic neuralgia and fibromyalgia, and generalized anxiety disorder. The evidence indicates a relationship between alpha2delta subunit binding and the modulation of processes that subserve neurotransmission. This modulation is characterized by a reduction of the excessive neurotransmitter release that is observed in certain neurological and psychiatric disorders.

PMID:
17222465
DOI:
10.1016/j.tips.2006.12.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center